Antiarrhythmic drug therapy in the management of atrial fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 8, Issue 10, 1997, Pages 1175-1189

  Ganz, Leonard I ^a,b   Antman, Elliott M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Antiarrhythmic agents; Antiarrhythmic therapy; Atrial fibrillation; Atrial flutter; Review

Indexed keywords

AMIODARONE; DISOPYRAMIDE; FLECAINIDE ACETATE; IBUTILIDE FUMARATE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; BLOOD DYSCRASIA; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0030862032     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1997.tb01005.x     Document Type: Review

References (100)

1. Prystowsky EN, Benson DW, Fuster V, et al: Management of patients with atrial fibrillation. Circulation 1996;93:1262-1277.
2. Falk RH, Knowlton AA, Bernard SA, et al: Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: A randomized, double-blinded trial. Ann Intern Med 1987;106:503-506.
3. Salerno DM, Dias VC, Kleiger RE, et al: Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. Am J Cardiol 1989;63:1046-1051.
4. Anderson S, Blanski L, Byrd RC, et al: Comparison of the efficacy and safety of esmolol, a short acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986;111:42-48.
5. Guarnieri T, Tomaselli G, Griffith LSC, et al: The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation. PACE 1991;14:1007-1012.
6. Halpern SW, Ellrodt G, Singh BN, et al: Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm. Br Heart J 1980;44:589-595.
7. Fenster PE, Comess KA, Marsh R, et al: Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983;106: 501-504.
8. Camm AJ, Ward D, Spurrell RAJ: The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias. Br J Clin Pharmacol 1979;8:441-449.
9. Deano DA, Wu D, Mautner RK, et al: The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. Chest 1977;71:597-606.
10. Kerin NZ, Faitel K, Naini M: The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: Amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med 1996; 156:49-53.
11. Borgeat A, Coy J-J, Maendly R, et al: Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58:496-498.
12. Hohnloser SH, van de Loo A, Baedeker F: Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-858.
13. Halinen MO, Huttunen M, Paakkinen S, et al: Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine trial). Am J Cardiol 1995;76:495-498.
14. Zehender M, Hohnloser S, Muller B, et al: et al: Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992;19:1054-1059.
15. Donovan KD, Dobb GJ, Coombs LJ, et al: Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991;67:137-141.
16. Suttorp MJ, Kingma JH, Lie-A-Huen L, et al: et al: Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation of flutter to sinus rhythm. Am J Cardiol 1989;63:693-696.
17. Vita JA, Friedman PL, Cantillon C, et al: Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol 1989;63:1275-1278.
18. Bellandi F, Cantini F, Pedone T, et al: Effectiveness of intravenous propafenone for conversion of recentonset atrial fibrillation: A placebo-controlled study. Clin Cardiol 1995;18:631-634.
19. Suttorp MJ, Kingma JH, Jessurun ER, et al: The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-1727.
20. Donovan KD, Power BM, Hockings BEF, et al: Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995;75:693-697.
21. Madrid AH, Moro C, Marín-Huerta E, et al: Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993;14:1127-1131.
22. Weiner P, Ganam R, Ganem R, et al: Clinical course of recent onset atrial fibrillation treated with oral propafenone. Chest 1994;105:1013-1016.
23. Boriani G, Capucci A, Lenzi T, et al: Propafenone for conversion of recent onset atrial fibrillation: A controlled comparison between oral loading dose and intravenous administration. Chest 1995;108:355-358.
24. Reimold SC, Cantillon CO, Friedman PL, et al: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563.
25. Capucci A, Boriani G, Botto GL, et al: Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994;74:503-505.
26. Sung RJ, Tan HL, Karagounis L, et al: Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study. Am Heart J 1995;129:739-748.
27. Hou Z-Y, Chang M-S, Chen C-Y, et al: Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: A randomized, digoxin-controlled study. Eur Heart J 1995;16:521-528.
28. Chapman MJ, Moran JL, O'Fathartaigh MS, et al: Management of atrial tachyarrhythmias in the critically ill: A comparison of intravenous procainamide and amiodarone. Int Care Med 1993;19:48-52.
29. Galve G, Rius T, Ballester R, et al: Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996;27:1079-1082.
30. Mostow ND, Vrobel TR, Noon D, et al: Rapid control of refractory atrial tachyarrhythmias with high dose oral amiodarone. Am Heart J 1990;120:1356-1363.
31. McCarthy ST, McCarthy GL, John S, et al: Amiodarone as a treatment for atrial fibrillation refractory to digoxin therapy. Br J Clin Pract Symp Suppl 1986;44:49-51.
32. Rowland E, McKenna WJ, Krikler DM: Amiodarone for the conversion of established atrial fibrillation and flutter. Br J Clin Pract Symp Suppl 1986;44:39-41.
33. Stambler BS, Wood MA, Ellenbogen KA, et al: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-1621.
34. Volgman AS, Stambler BS, Kappagoda C, et al: Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter. PACE 1996;19:608.
35. Lündstrom T, Rydér L: Chronic atrial fibrillation: Long-term results of direct current cardioversion. Acta Med Scand 1988;223:53-59.
36. Falk RH: Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992;117:141-150.
37. Antman EM: Atrial fibrillation and flutter: Maintaining stability of sinus rhythm versus ventricular rate control. J Cardiovasc Electrophysiol 1995;6:962-971.
38. The NHLBI AFFIRM Investigators: Atrial Fibrillation Follow-Up Investigation of Rhythm Management - The AFFIRM study design. Am J Cardiol 1997;79:1198-1202.
39. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
40. Karlson BW, Torstensson I, Abjorn C, et al: Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation: A placebo-controlled one year follow-up study. Eur Heart J 1988;9: 284-290.
41. Cohen IS, Jick H, Cohen SI: Adverse reactions to quinidine in hospitalized patients: Findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977;20:151-163.
42. Lawson DH, Jick H: Adverse reactions to procainamide. Br J Clin Pharmacol 1977;4:507-511.
43. Bauman JL, Callastegui J, Strasberg B, et al: Long-term therapy with disopyramide phosphate: Side effects and effectiveness. Am Heart J 1986;111:654-660.
44. Anderson JL, Gilbert EM, Alpert BL, et al: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-1570.
45. Pritchett ELC, DaTorre SD, Platt ML, et al: Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies. J Am Coll Cardiol 1991;17:297-303.
46. Lau C-P, Leung W-H, Wong C-K: A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992;124:645-650.
47. Naccarelli GV, Dorian P, Hohnloser SH, et al., for the Flecainide Multicenter Atrial Fibrillation Study Group: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:53A-59A.
48. van Gelder IC, Crijns HJGM, van Gilst WH, et al: Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321.
49. UK Propafenone PSVT Study Group: A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2550-2557.
50. Pritchett ELC, McCarthy EA, Wilkinson WE: Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-544.
51. Antman EM, Beamer AD, Cantillon C, et al: Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12:1005-1011.
52. CAST Investigators: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
53. Chimiento M, Cullen MT, Casaderi G: Safety of long-term flecainide and propatenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the flecainide and propafenone Italian study investigators. Am J Cardiol 1996;77:60A-65A.
54. Hohnloser SH, Zabel M: Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;70:3A-10A.
55. Falk RH: Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-111.
56. Podrid PJ, Anderson JL: Safety and tolerability of long-term propafenone for supraventricular tachyarrhythmias. Am J Cardiol 1996;78:430-434.
57. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al: Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990;66:755-757.
58. Singh S, Saini RK, DiMarco J, et al: Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol 1991;68:1227-1230.
59. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation 1990;82:1932-1939.
60. Betapace® package insert. Berlex Laboratories, 1994.
61. Waldo AL, Camm AJ, deRuyter H, et al: Effect of dsotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
62. Podrid PJ: Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995;122:689-700.
63. Vitolo E, Tronci M, Larovere MT, et al: Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;6:431-444.
64. Gosselink AT, Crijns HGM, Van Gelder IC, et al: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
65. Chun SH, Sager PT, Stevenson WG, et al: Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
66. Middlekauff HR, Wiener I, Saxon LA, et al: Low-dose amiodarone for atrial fibrillation: Time for a prospective study? Ann Intern Med 1992;116:1017-1020.
67. Wijffels MCEF, Kirchof CJHJ, Dorland R, et al: Atrial fibrillation begets atrial fibrillation: A study in awake, chronically instrumented goats. Circulation 1995;92:1954-1968.
68. Grey E, Silverman DI: Efficacy of type IC antiarrhythmic agents for treatment of resistant atrial fibrillation. PACE 1993;16:2235-2240.
69. Antman EM, Beamer AD, Cantillon C, et al: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-707.
70. Ganz LI, Shea JB, Reimold SC, et al: et al: Long-term follow-up in patients with medically refractory atrial fibrillation treated with propafenone and sotalol. (Abstract) J Am Coll Cardiol 1996;27:47A.
71. Crijns HJ, van Gelder IC, Gilst WH, et al: Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or flutter. Am J Cardiol 1991;68:335-341.
72. van Gelder IC, Crijns HJGM, Tieleman RG, et al: Chronic atrial fibrillation: Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996;156:2585-2592.
73. Kall JG, Kopp DE, Kinder CA, et al: Sotalol versus low-dose amiodarone for maintenance of sinus rhythm in patients with atrial fibrillation. (Abstract) J Am Coll Cardiol 1996;27:46A.
74. Kerin NZ, Somberg J: Proarrhythmia: Definition, risk factors, causes, treatments, and controversies. Am Heart J 1994;128:575-585.
75. Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532.
76. Roden DM, Murray KT: Pharmacokinetics, pharmacodynamics, and pharmacogenetics. In Zipes DP, Jalife J, eds: Cardiac Electrophysiology: From Cell to Bedside. Second Edition. WB Saunders Co., Philadelphia, 1995, pp. 1287-1296.
77. Thomson GW: Quinidine as a cause of sudden death. Circulation 1956;14:757-765.
78. Selzer A, Wray HW: Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
79. Roden DM: Torsade de pointes. Clin Cardiol 1993;683-686.
80. Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088-1093.
81. Hohnloser SH, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects: A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535.
82. Mattioni TA, Zheutlin TA, Sarmieento JJ, et al: Amiodarone in patients with previous drug-mediated torsade de pointes: Long-term safety and efficacy. Ann Intern Med 1989;111:574-580.
83. Middlekauff HR, Stevenson WG, Saxon LA, et al: Amiodarone and torsade de pointes in patients with advanced heart failure. Am J Cardiol 1995;76:499-502.
84. Feld GK, Chen P-S, Nicod P, et al: Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990;66:378-383.
85. Crijns HJ, van Gelder IC, Lie KI: Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988;62: 1303-1306.
86. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al: Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990;66:755-757.
87. Maisel WH, Kuntz KM, Reimold SC, et al: Risk of initiating antiarrhythmic drug therapy for atrial fibrillation. Ann Intern Med 1997;127:281-284.
88. Reiffel JA, Correia J: "In the absence of structural heart disease . . ." What is it and why does it matter in antiarrhythmic drug therapy? Am Heart J 1994;128:626-629.
89. Gottlieb SS, Riggio DW, Lauria S, et al: High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol 1994;23:560-564.
90. Martyn R, Somberg JC, Kerin NZ: Proarrhythmia of nonantiarrhythmic drugs. Am Heart J 1993;126:201-205.
91. Byrne-Quinn E, Wing AJ: Maintenance of sinus rhythm after DC reversion of atrial fibrillation: A double-blind controlled trial of long-acting quinidine bisulphate. Br Heart J 1970;32:370-376.
92. Härtel G, Louhija A, Konttinen A, et al: Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J 1970;32:57-60.
93. Hillestad L, Bjerkelund C, Dale J, et al: Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: A controlled clinical study. Br Heart J 1971;33:518-521.
94. Södermark T, Jonsson B, Olsson A, et al: Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: A multicentre study from Stockholm. Br Heart J 1975;37:486-492.
95. Rasmussen K, Wang H, Fausa D: Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation: A controlled clinical trial. Acta Med Scand Suppl 1981;645:23-28.
96. Boissel JP, Wolf E, Gillet J, et al: Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981;2:49-55.
97. Lloyd EA, Gersh BJ, Forman R: The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation: A double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J 1984;65:367-369.
98. Rasmussen K, Andersen A, Abrahamsen AM, et al: Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation. (Abstract) Eur Heart J 1988;9(Suppl):52.
99. Graboys TB, Podrid PJ, town B: Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983;106:870-876.
100. Gold RL, Haffajee CI, Charos G, et al: Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57:124-127.